Nutriband Inc. (NTRB)
5.66
-0.11 (-1.91%)
At close: Apr 03, 2025, 1:29 PM
-1.91% (1D)
| Bid | 4.05 |
| Market Cap | 62.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -7.97 |
| Forward PE | -14.07 |
| Analyst | Buy |
| Ask | 5.67 |
| Volume | 5,749 |
| Avg. Volume (20D) | 213,088 |
| Open | 5.56 |
| Previous Close | 5.77 |
| Day's Range | 5.50 - 5.72 |
| 52-Week Range | 3.20 - 11.78 |
| Beta | 0.32 |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB
Website https://nutriband.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NTRB stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 129.68% from the latest price.
Stock Forecasts1 month ago
+17.09%
Nutriband shares are trading higher after the comp...
Unlock content with
Pro Subscription
2 months ago
+40.88%
Nutriband shares are trading higher after Noble Capital Markets initiated coverage on the stock with an Outperform rating and a $13 price target.